Index RUT
P/E -
EPS (ttm) -1.74
Insider Own 65.49%
Shs Outstand 158.83M
Perf Week 5.08%
Market Cap 1.92B
Forward P/E -
EPS next Y -1.60
Insider Trans -0.10%
Shs Float 55.23M
Perf Month 1.70%
Income -274.18M
PEG -
EPS next Q -0.40
Inst Own 27.62%
Short Float 18.08%
Perf Quarter 22.60%
Sales 0.00M
P/S -
EPS this Y 58.94%
Inst Trans -
Short Ratio 12.34
Perf Half Y -20.54%
Book/sh 2.38
P/B 5.03
EPS next Y -7.15%
ROA -71.73%
Short Interest 9.98M
Perf Year -
Cash/sh 2.32
P/C 5.16
EPS next 5Y -
ROE -77.08%
52W Range 8.33 - 21.00
Perf YTD -29.68%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -71.91%
52W High -42.90%
Beta 3.69
Dividend TTM -
Quick Ratio 17.22
Sales past 5Y 0.00%
Gross Margin -
52W Low 43.94%
ATR (14) 0.67
Dividend Ex-Date -
Current Ratio 17.22
EPS Y/Y TTM -100.60%
Oper. Margin 0.00%
RSI (14) 56.81
Volatility 6.48% 5.68%
Employees 124
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 23.14
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -45.53%
Payout -
Rel Volume 0.64
Prev Close 12.03
Sales Surprise -
EPS Surprise 0.54%
Sales Q/Q -
Earnings Aug 06 BMO
Avg Volume 808.83K
Price 11.99
SMA20 4.84%
SMA50 3.66%
SMA200 -6.68%
Trades
Volume 422,536
Change -0.33%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-22-24 Initiated
Needham
Buy
$23
Jul-08-24 Initiated
Mizuho
Outperform
$20
Dec-12-23 Initiated
Deutsche Bank
Hold
$13
Oct-10-23 Initiated
William Blair
Outperform
$26
Oct-10-23 Initiated
Stifel
Buy
$26
Oct-10-23 Initiated
RBC Capital Mkts
Outperform
$24
Oct-10-23 Initiated
JP Morgan
Overweight
$21
Oct-10-23 Initiated
Guggenheim
Buy
$22
Oct-10-23 Initiated
BofA Securities
Buy
$18
Aug-14-24 07:00AM
Aug-06-24 01:54PM
07:00AM
Jul-01-24 01:00AM
Jun-20-24 07:00AM
08:52AM
Loading…
May-14-24 08:52AM
07:00AM
May-07-24 01:54PM
10:20AM
07:00AM
May-06-24 07:00AM
Apr-16-24 11:28AM
Apr-15-24 04:20PM
(Investor's Business Daily) -17.48%
12:17PM
08:45AM
07:47AM
Loading…
07:47AM
06:36AM
06:30AM
Mar-13-24 07:00AM
Mar-07-24 02:52PM
07:00AM
Jan-22-24 07:00AM
Jan-10-24 08:32AM
Jan-02-24 07:00AM
Dec-17-23 12:35PM
Dec-12-23 07:00AM
Nov-27-23 07:00AM
Nov-01-23 07:00AM
Oct-30-23 07:00AM
Oct-10-23 07:00AM
07:54PM
Loading…
Sep-28-23 07:54PM
(InvestorPlace) +11.84%
+6.73%
Sep-27-23 06:50PM
Sep-18-23 12:35PM
Sep-14-23 08:49PM
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Lenz Robert A. Officer Sep 12 '24 Proposed Sale 11.43 32,948 376,665 Sep 12 05:18 PM Pinto Joshua Chief Financial Officer Aug 27 '24 Sale 11.39 15,693 178,806 138,965 Aug 27 05:58 PM Pinto Joshua Chief Financial Officer Aug 26 '24 Sale 11.78 31,642 372,588 154,658 Aug 26 06:17 PM Pinto Joshua Chief Financial Officer Aug 22 '24 Sale 11.63 28,496 331,468 210,469 Aug 26 06:17 PM Pinto Joshua Chief Financial Officer Aug 23 '24 Sale 11.59 24,169 280,005 186,300 Aug 26 06:17 PM Pinto Joshua Officer Aug 22 '24 Proposed Sale 11.90 100,000 1,190,000 Aug 22 09:48 AM Burow Kristina Director Nov 13 '23 Buy 11.75 31,653 371,923 4,127,850 Nov 15 06:55 PM Burow Kristina Director Nov 14 '23 Buy 11.98 3,357 40,217 4,131,207 Nov 15 06:55 PM ARCH Venture Partners XII, LLC 10% Owner Nov 13 '23 Buy 11.75 31,653 371,923 4,127,850 Nov 15 06:54 PM ARCH Venture Partners XII, LLC 10% Owner Nov 14 '23 Buy 11.98 3,357 40,217 4,131,207 Nov 15 06:54 PM Burow Kristina Director Nov 08 '23 Buy 11.03 92,251 1,017,821 4,047,843 Nov 13 07:01 PM Burow Kristina Director Nov 09 '23 Buy 10.53 31,079 327,262 4,078,922 Nov 13 07:01 PM Burow Kristina Director Nov 10 '23 Buy 11.49 17,275 198,481 4,096,197 Nov 13 07:01 PM ARCH Venture Partners XII, LLC 10% Owner Nov 08 '23 Buy 11.03 92,251 1,017,821 4,047,843 Nov 13 07:00 PM ARCH Venture Partners XII, LLC 10% Owner Nov 09 '23 Buy 10.53 31,079 327,262 4,078,922 Nov 13 07:00 PM ARCH Venture Partners XII, LLC 10% Owner Nov 10 '23 Buy 11.49 17,275 198,481 4,096,197 Nov 13 07:00 PM Burow Kristina Director Nov 06 '23 Buy 11.55 43,082 497,597 3,925,400 Nov 07 07:00 PM Burow Kristina Director Nov 07 '23 Buy 11.50 30,192 347,208 3,955,592 Nov 07 07:00 PM Burow Kristina Director Nov 03 '23 Buy 11.38 22,420 255,140 3,882,318 Nov 07 07:00 PM ARCH Venture Partners XII, LLC 10% Owner Nov 06 '23 Buy 11.55 43,082 497,597 3,925,400 Nov 07 06:59 PM ARCH Venture Partners XII, LLC 10% Owner Nov 07 '23 Buy 11.50 30,192 347,208 3,955,592 Nov 07 06:59 PM ARCH Venture Partners XII, LLC 10% Owner Nov 03 '23 Buy 11.38 22,420 255,140 3,882,318 Nov 07 06:59 PM Burow Kristina Director Sep 28 '23 Buy 13.44 41,951 563,699 3,825,338 Sep 29 06:55 PM Burow Kristina Director Sep 29 '23 Buy 13.98 34,560 483,149 3,859,898 Sep 29 06:55 PM ARCH Venture Partners XII, LLC 10% Owner Sep 28 '23 Buy 13.44 41,951 563,699 3,825,338 Sep 29 06:53 PM ARCH Venture Partners XII, LLC 10% Owner Sep 29 '23 Buy 13.98 34,560 483,149 3,859,898 Sep 29 06:53 PM Burow Kristina Director Sep 26 '23 Buy 11.73 34,000 398,820 3,758,883 Sep 27 08:19 PM Burow Kristina Director Sep 27 '23 Buy 12.31 24,504 301,644 3,783,387 Sep 27 08:19 PM ARCH Venture Partners XII, LLC 10% Owner Sep 26 '23 Buy 11.73 34,000 398,820 3,758,883 Sep 27 08:18 PM ARCH Venture Partners XII, LLC 10% Owner Sep 27 '23 Buy 12.31 24,504 301,644 3,783,387 Sep 27 08:18 PM ARCH Venture Partners XII, LLC 10% Owner Sep 25 '23 Buy 11.22 60,740 681,464 3,724,883 Sep 25 09:38 PM ARCH Venture Partners XII, LLC 10% Owner Sep 22 '23 Buy 11.14 40,000 445,600 3,664,143 Sep 25 09:38 PM Burow Kristina Director Sep 25 '23 Buy 11.22 60,740 681,464 3,724,883 Sep 25 09:37 PM Burow Kristina Director Sep 22 '23 Buy 11.14 40,000 445,600 3,664,143 Sep 25 09:37 PM Burow Kristina Director Sep 19 '23 Buy 17.00 1,500,000 25,500,000 3,624,143 Sep 20 06:23 AM ARCH Venture Partners X, LLC 10% Owner Sep 19 '23 Buy 17.00 1,500,000 25,500,000 3,624,143 Sep 20 06:16 AM ARCH Venture Partners X, LLC 10% Owner Sep 19 '23 Buy 17.00 1,500,000 25,500,000 3,624,143 Sep 20 06:15 AM Gosebruch Henry O President & CEO Sep 19 '23 Buy 12.62 15,000 189,370 15,000 Sep 19 09:47 PM AMGEN INC 10% Owner Sep 19 '23 Buy 17.00 1,764,705 29,999,985 35,368,653 Sep 19 07:52 PM
Index RUT
P/E -
EPS (ttm) -3.06
Insider Own 35.41%
Shs Outstand 97.87M
Perf Week -8.05%
Market Cap 433.18M
Forward P/E -
EPS next Y -2.10
Insider Trans -0.03%
Shs Float 64.46M
Perf Month 9.05%
Income -299.80M
PEG -
EPS next Q -0.80
Inst Own 77.36%
Short Float 11.16%
Perf Quarter 3.83%
Sales 0.00M
P/S -
EPS this Y 45.60%
Inst Trans -
Short Ratio 6.54
Perf Half Y -44.64%
Book/sh 5.71
P/B 0.76
EPS next Y 28.97%
ROA -40.33%
Short Interest 7.20M
Perf Year -60.62%
Cash/sh 6.36
P/C 0.68
EPS next 5Y -
ROE -43.79%
52W Range 3.36 - 11.83
Perf YTD -41.82%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -52.66%
52W High -63.31%
Beta 2.27
Dividend TTM -
Quick Ratio 7.86
Sales past 5Y 0.00%
Gross Margin -
52W Low 29.17%
ATR (14) 0.42
Dividend Ex-Date -
Current Ratio 7.86
EPS Y/Y TTM -
Oper. Margin 0.00%
RSI (14) 41.48
Volatility 8.53% 8.33%
Employees 130
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.86
Target Price 11.40
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -222.51%
Payout -
Rel Volume 0.71
Prev Close 4.70
Sales Surprise -
EPS Surprise -10.26%
Sales Q/Q -
Earnings Aug 13 AMC
Avg Volume 1.10M
Price 4.34
SMA20 -7.68%
SMA50 -17.98%
SMA200 -27.51%
Trades
Volume 630,618
Change -7.66%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-14-24 Downgrade
H.C. Wainwright
Buy → Neutral
$18 → $6
Jul-08-24 Upgrade
Wells Fargo
Equal Weight → Overweight
$13
Dec-13-23 Initiated
Wells Fargo
Equal Weight
$11
Dec-08-23 Initiated
Citigroup
Neutral
$8
Sep-13-23 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$19
Sep-05-23 Initiated
H.C. Wainwright
Buy
$44
May-30-23 Initiated
TD Cowen
Outperform
May-30-23 Initiated
Piper Sandler
Overweight
$68
May-30-23 Initiated
Morgan Stanley
Overweight
May-30-23 Initiated
Jefferies
Buy
$31
Sep-12-24 01:30AM
Sep-10-24 07:00AM
Aug-22-24 07:00AM
Aug-13-24 04:00PM
03:37AM
04:30PM
Loading…
Aug-06-24 04:30PM
Jun-05-24 07:00AM
May-29-24 07:00AM
May-15-24 11:54AM
May-09-24 08:01AM
08:00AM
Apr-29-24 04:05PM
Mar-28-24 10:53PM
04:05PM
Mar-27-24 04:01PM
11:12AM
Loading…
Mar-21-24 11:12AM
Mar-20-24 07:00AM
12:39AM
Mar-11-24 10:04AM
(FierceBiotech.com) +10.96%
08:02AM
08:00AM
Feb-15-24 04:05PM
Jan-10-24 11:30AM
Jan-04-24 09:56AM
Jan-01-24 09:35AM
Dec-27-23 10:45AM
Dec-20-23 04:30PM
Dec-19-23 12:13AM
Dec-18-23 04:14PM
Dec-12-23 09:25PM
09:35AM
Loading…
Dec-11-23 09:35AM
Dec-04-23 03:00PM
08:00AM
Nov-30-23 04:30PM
Nov-28-23 05:55PM
(GlobeNewswire) -32.41%
+8.16%
01:44PM
07:24AM
Nov-27-23 09:09PM
04:30PM
Nov-20-23 11:01AM
Nov-16-23 06:42PM
04:11PM
Nov-07-23 05:11PM
04:05PM
Nov-06-23 07:00AM
Oct-31-23 04:30PM
Oct-18-23 09:00PM
Oct-03-23 07:00AM
Sep-15-23 05:39PM
Sep-11-23 04:05PM
Sep-06-23 07:00AM
Aug-15-23 07:22PM
Aug-14-23 04:05PM
Aug-07-23 04:30PM
Jul-18-23 07:00AM
Jun-15-23 04:05PM
May-09-23 04:10PM
May-05-23 07:08PM
(The Wall Street Journal)
ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Becker Daniel J. Director Jul 17 '24 Sale 6.86 1 7 2,999 Jul 19 06:18 PM Lin Shao-Lee Chief Executive Officer Apr 01 '24 Sale 6.63 9,961 66,024 1,577,374 Apr 03 06:18 PM Lin Shao-Lee Chief Executive Officer Feb 20 '24 Sale 7.60 15,701 119,403 1,587,335 Feb 22 07:04 PM Lin Shao-Lee Chief Executive Officer Jan 02 '24 Sale 7.41 10,691 79,188 1,603,036 Jan 04 06:09 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite